Stockscreener 앱 받기
33.40
2.77%
0.90
전일 마감가:
$32.50
열려 있는:
$32.8
하루 거래량:
711.08K
Relative Volume:
1.38
시가총액:
$1.62B
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+19.89%
1개월 성능:
+15.41%
6개월 성능:
+125.68%
1년 성능:
+165.08%
1일 변동 폭
$31.61
$33.85
1주일 범위
$26.91
$33.85
52주 변동 폭
$5.485
$33.85
Oruka Therapeutics Inc Stock (ORKA) Company Profile
명칭
Oruka Therapeutics Inc
전화
650-606-7910
주소
855 OAK GROVE AVE., MENLO PARK
ORKA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ORKA
Oruka Therapeutics Inc
|
33.40 | 1.57B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Oruka Therapeutics Inc Stock (ORKA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-18 | 개시 | Piper Sandler | Overweight |
| 2025-11-13 | 개시 | Jefferies | Buy |
| 2025-10-27 | 개시 | Guggenheim | Buy |
| 2025-10-13 | 개시 | Barclays | Overweight |
| 2025-05-22 | 개시 | BTIG Research | Buy |
| 2025-02-04 | 개시 | Wolfe Research | Outperform |
| 2024-10-11 | 개시 | Stifel | Buy |
| 2024-10-07 | 개시 | H.C. Wainwright | Buy |
| 2024-09-17 | 개시 | Leerink Partners | Outperform |
| 2024-09-16 | 개시 | TD Cowen | Buy |
| 2024-09-13 | 개시 | Jefferies | Buy |
| 2018-02-27 | 개시 | Ascendiant Capital Markets | Buy |
| 2013-10-09 | 개시 | Dawson James | Buy |
모두보기
Oruka Therapeutics Inc 주식(ORKA)의 최신 뉴스
Oruka Therapeutics stock hits 52-week high at 32.65 USD By Investing.com - Investing.com Nigeria
Oruka Therapeutics stock hits 52-week high at 32.65 USD - Investing.com India
Oruka Therapeutics (NASDAQ:ORKA) Sets New 12-Month HighHere's Why - MarketBeat
Pullback Watch: What is Oruka Therapeutics Incs book value per shareJuly 2025 Review & Fast Entry Momentum Alerts - baoquankhu1.vn
Oruka Therapeutics (ORKA) Price Target Increased by 12.54% to 56.44 - Nasdaq
Clear Street raises Oruka Therapeutics stock price target on promising drug data - Investing.com Canada
Oruka reports positive interim data for ORKA-002 in Phase 1 trial - Investing.com Nigeria
Oruka Reports Positive Interim Phase 1 Data for ORKA-002, Advances ORKA-001 - Dermatology Times
BTIG Research Issues Positive Forecast for Oruka Therapeutics (NASDAQ:ORKA) Stock Price - MarketBeat
Oruka reports positive interim data for ORKA-002 in Phase 1 trial By Investing.com - Investing.com South Africa
Oruka Therapeutics, Inc. Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of Everlong-B Trial of ORKA-001 - marketscreener.com
Earnings Risk: Is OPFI affected by consumer sentimentJuly 2025 Highlights & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Oruka Therapeutics (NASDAQ:ORKA) Earns Buy Rating from Analysts at UBS Group - Defense World
Aug Outlook: Why Oruka Therapeutics Inc. stock is favored by top institutions2025 Retail Activity & Real-Time Volume Spike Alerts - Улправда
Oruka Therapeutics, Inc. (ORKA) Stock Analysis: Unpacking a 97.60% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Oruka Therapeutics (NASDAQ:ORKA) Rating Increased to Strong-Buy at UBS Group - MarketBeat
ORKA-001 psoriasis trial: Fresh phase 2 update and what it means for investors - MSN
Does UBS’s New Coverage Reframe Oruka Therapeutics (ORKA) as a Peptide Platform, Not Just a Biotech? - Sahm
How buybacks impact Oruka Therapeutics Inc. stock valueJuly 2025 Macro Moves & Risk Controlled Swing Alerts - ulpravda.ru
Can Oruka Therapeutics Inc. stock attract ESG capital inflowsJuly 2025 Trade Ideas & Reliable Breakout Stock Forecasts - Улправда
Will Oruka Therapeutics Inc. (HQ1) stock top growth indexes2025 Market WrapUp & Precise Swing Trade Entry Alerts - ulpravda.ru
Why Oruka Therapeutics Inc. stock is a must watch in 2025Earnings Beat & AI Powered Market Entry Strategies - Улправда
Is Oruka Therapeutics Inc. (HQ1) stock undervalued historicallyJuly 2025 Technicals & Reliable Price Breakout Alerts - Улправда
What sentiment indicators say about Oruka Therapeutics Inc. stockJuly 2025 Institutional & Technical Buy Zone Confirmations - Улправда
Is Oruka Therapeutics Inc. stock a dividend growth opportunity - Улправда
Dental EconomicsOruka Therapeutics, Inc.Common Stock (Nasdaq:ORKA) Detailed Stock Data - FinancialContent
UBS initiates coverage of Oruka Therapeutics (ORKA) with buy recommendation - MSN
Oruka Therapeutics stock initiated with Buy rating at UBS on cancer drug potential - Investing.com Canada
Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Oruka Therapeutics: ORKA-001 For Psoriasis In Focus As 2026 Phase 2 Data Nears - Seeking Alpha
Oruka Therapeutics (NASDAQ:ORKA) Trading Down 8.3%What's Next? - MarketBeat
Insider Sell Alert: Laura Sandler Sells 13,000 Shares of Oruka T - GuruFocus
Oruka Therapeutics COO Sandler sells $370,795 in shares By Investing.com - Investing.com Canada
Oruka Therapeutics COO Sandler sells $370,795 in shares - Investing.com UK
Oruka Therapeutics (NASDAQ:ORKA) Stock Price Up 4.3% – Time to Buy? - Defense World
Oruka Therapeutics (NASDAQ:ORKA) Shares Up 4.3%Should You Buy? - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Trading Down 3.3%Time to Sell? - MarketBeat
Wolfe Research Initiates Coverage of Oruka Therapeutics (ORKA) with Outperform Recommendation - MSN
Rigel Pharmaceuticals (NASDAQ:RIGL) and Oruka Therapeutics (NASDAQ:ORKA) Financial Survey - Defense World
Oruka Therapeutics inks exclusive license deal with Paragon - MSN
Oruka Therapeutics (ORKA): Valuation Check After Board Appointment of Commercial Veteran Chris Martin - Sahm
Oruka Therapeutics stock hits 52-week high at 32.31 USD By Investing.com - Investing.com Australia
Oruka Therapeutics (NASDAQ:ORKA) Reaches New 12-Month HighHere's What Happened - MarketBeat
Oruka Therapeutics stock hits 52-week high at 32.31 USD - Investing.com India
Financial Enhancement Group LLC Takes Position in Oruka Therapeutics, Inc. $ORKA - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Insider Sells $214,270.00 in Stock - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Shares Up 11.3%Here's What Happened - MarketBeat
Piper Sandler Begins Coverage on Oruka Therapeutics (NASDAQ:ORKA) - MarketBeat
How Oruka Therapeutics Inc. stock compares to growth peersWeekly Gains Report & AI Based Buy and Sell Signals - Улправда
ORKA-001 Psoriasis Trial: Fresh Phase 2 Update and What It Means for Investors - TipRanks
Oruka Therapeutics Inc (ORKA) 재무 분석
Oruka Therapeutics Inc (ORKA)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Oruka Therapeutics Inc 주식 (ORKA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Goncalves Joana | Chief Medical Officer |
Jan 15 '26 |
Sale |
31.81 |
7,000 |
222,704 |
1,518 |
| Sandler Laura Lee | Chief Operating Officer |
Jan 02 '26 |
Option Exercise |
7.80 |
5,000 |
39,000 |
218,084 |
| Sandler Laura Lee | Chief Operating Officer |
Jan 02 '26 |
Sale |
28.52 |
13,000 |
370,795 |
205,084 |
4.73%
0.92%
자본화:
|
볼륨(24시간):